- Home
- XPRO vs ANIP Comparison
XPRO vs ANIP Comparison
Compare XPRO & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPRO
- ANIP
- Stock Information
- Founded
- XPRO 1938
- ANIP 2001
- Country
- XPRO United States
- ANIP United States
- Employees
- XPRO N/A
- ANIP N/A
- Industry
- XPRO Oilfield Services/Equipment
- ANIP Biotechnology: Pharmaceutical Preparations
- Sector
- XPRO Energy
- ANIP Health Care
- Exchange
- XPRO Nasdaq
- ANIP Nasdaq
- Market Cap
- XPRO 1.2B
- ANIP 1.2B
- IPO Year
- XPRO 2013
- ANIP N/A
- Fundamental
- Price
- XPRO $9.92
- ANIP $68.02
- Analyst Decision
- XPRO Buy
- ANIP Strong Buy
- Analyst Count
- XPRO 3
- ANIP 8
- Target Price
- XPRO $22.00
- ANIP $79.75
- AVG Volume (30 Days)
- XPRO 1.4M
- ANIP 361.8K
- Earning Date
- XPRO 04-24-2025
- ANIP 05-09-2025
- Dividend Yield
- XPRO N/A
- ANIP N/A
- EPS Growth
- XPRO N/A
- ANIP N/A
- EPS
- XPRO 0.45
- ANIP N/A
- Revenue
- XPRO $1,712,802,000.00
- ANIP $614,376,000.00
- Revenue This Year
- XPRO $3.75
- ANIP $27.62
- Revenue Next Year
- XPRO $3.26
- ANIP $7.71
- P/E Ratio
- XPRO $22.09
- ANIP N/A
- Revenue Growth
- XPRO 13.22
- ANIP 26.20
- 52 Week Low
- XPRO $9.66
- ANIP $52.50
- 52 Week High
- XPRO $24.50
- ANIP $70.00
- Technical
- Relative Strength Index (RSI)
- XPRO 34.41
- ANIP 66.14
- Support Level
- XPRO $10.24
- ANIP $65.28
- Resistance Level
- XPRO $10.96
- ANIP $69.33
- Average True Range (ATR)
- XPRO 0.41
- ANIP 2.32
- MACD
- XPRO 0.02
- ANIP 0.29
- Stochastic Oscillator
- XPRO 16.67
- ANIP 83.54
About XPRO Expro Group Holdings N.V.
Expro Group Holdings NV offers products and services that span the well life cycle, including well construction, well flow management, well intervention and integrity, and subsea well access. It maintains operations around the world and specializes in offshore production solutions. It also provides production optimization for both onshore and offshore applications. The company has four operating segments: North and Latin America (NLA); Europe and Sub-Saharan Africa (ESSA); Middle East and North Africa (MENA), and Asia-Pacific (APAC). The majority of its revenue is derived from North and Latin America (NLA) segment.
About ANIP ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.